Simian-human immunodeficiency virus (SHIV) carrying the envelope from the clade B clinical human immunodeficiency virus type 1 (HIV-1) isolate MNA, designated SHIV MNA, was generated through intracellular homologous recombination. SHIV MNA inherited biological properties from the parental HIV-1, including CCR5 co-receptor preference, resistance to neutralization by the anti-V3 loop mAb KD-247 and loss of resistance in the presence of the CD4-mimic small-molecule YYA-021. SHIV MNA showed productive replication in rhesus macaque PBMCs. Experimental infection of a rhesus macaque with SHIV MNA caused a transient but high titre of plasma viral RNA and a moderate antibody response. Immunoglobulin in the plasma at 24 weeks post-infection was capable of neutralizing SHIV MNA in the presence but not in the absence of YYA-021. SHIV MNA could serve a model for development of novel therapeutic interventions based on CD4-mimic-mediated conversion of envelope protein susceptible to antibody neutralization.
Control of primate lentiviral infection by antibodies directed against viral envelope protein is theoretically feasible. This was confirmed by the successful protection of macaque monkeys from challenge inoculation with simian-human immunodeficiency virus (SHIV) carrying an envelope protein (Env). Env was derived from a laboratory strain of human immunodeficiency virus type 1 (HIV-1) through the passive immunization of neutralizing mAbs directed against HIV-1 ( Mascola et al., 2000; Nishimura et al., 2003) . This neutralization is consistent with the results normally seen in cell culture systems.
In contrast, clinical isolates of HIV-1 that have not been subjected to extensive passage in T-cell lines are generally resistant to antibody-mediated neutralization (Moore et al., 1995) . It has been shown that virus in infected individuals is under selective pressure to develop a variety of means to evade attack by neutralizing antibodies, including sequence variation, glycosylation, tertiary structural shielding formed by the Env trimer and the rapid kinetics of conformational changes of Env, which affect fusion between the viral envelope and the plasma membrane of target cells (Kong & Sattentau, 2012) . Although four major neutralizing epitopes have been identified in HIV-1 Env (i.e. the V1/V2 loop, the glycan-V3 site and CD4-binding site of gp120, and the membrane-proximal external region of gp41), for reasons that are as yet unclear few reports of antibodies directed against these epitopes capable of neutralizing a broad range of isolates have been published (Kwong & Mascola, 2012) . High titres of antibodies directed against the V3 loop are elicited in individuals during the early phase of HIV-1 infection, but these are incapable of neutralizing the virus because the epitope in functional Env trimer is probably shielded from the antibody (Davis et al., 2009b) . Therefore, it is necessary to develop a means of rendering these epitopes accessible to the antibodies, to make antibody-mediated suppression of HIV-1 a valid therapeutic option.
It has been reported that neutralization mediated by antibodies directed against the V3 loop (Lusso et al., 2005) or CD4-induced epitope (CD4i) (Thali et al., 1993) can be enhanced in the presence of soluble CD4 (sCD4). It is known that the interaction of Env with sCD4 drives a conformational change of the viral protein and makes the cryptic/occult epitopes accessible to these antibodies (Wyatt et al., 1998) . Small molecules that emulate sCD4 for its interaction and subsequent induction of conformational change of Env may be employed to intensify antibody-mediated interventions against HIV-1 infection. Compounds with the above-mentioned properties (i.e. NBD-556 and NBD-557) have been reported previously (Zhao et al., 2005) . NBD-556 has been shown in cell culture to interact with the CD4-binding pocket to induce a conformational change in gp120 (Madani et al., 2008) and enhance exposure of the Env of primary HIV-1 isolates to neutralizing epitopes .
The present study was performed to evaluate smallmolecule CD4-mimic-based enhancement of antibodymediated virus neutralization, in the context of virus infection in vivo. The SHIV/macaque monkey model of AIDS is particularly suitable for such studies, as SHIV carries the HIV-1 Env and the neutralization sensitivity of SHIV is comparable to that of the parental HIV-1 (Shibata & Adachi, 1992) .
As NBD-556, unlike sCD4, inhibits infection with select HIV-1 isolates , we generated a new SHIV strain carrying Env, the sensitivity of which to antibody-mediated neutralization is enhanced in the presence of a CD4 mimic. An HIV-1 isolate (MNA), previously designated primary isolate HIV-1 Pt.3, was used as the source of Env, as the viral protein has been reported to interact with NBD-556 . While the virus belongs to a distinct subset of HIV-1 isolates, as mentioned above, it has also been reported to utilize the CCR5 molecule to gain entry into target cells, a property that is shared by the majority of HIV-1 strains . A mAb directed against the tip of the V3 loop (GPGR motif), KD-247 (Eda et al., 2006) , was employed to assess this concept, as HIV-1 MNA is resistant to KD-247-mediated neutralization, despite carrying the exact epitope sequence in the tip of the V3 loop, and is converted to being sensitive to the antibody by NBD-556 in a dosedependent manner .
First, we reproduced the results of Yoshimura et al. (2010) using a neutralization assay employing TZM-bl cells (Platt et al., 1998) , obtained from the National Institutes of Health (NIH) AIDS Reagent Program (Fig. S1 , available in JGV Online). The virus was resistant to KD-247, as described previously, and required almost 50 mg ml 21 of the antibody to achieve 50 % neutralization in our assay. However, the observed resistance was eliminated in the presence of 2 mM NBD-556; 50 % neutralization was achieved in the presence of~0.1 mg KD-247 ml 21 , corresponding to 1/500 of the amount of the antibody to achieve the same degree of neutralization in the absence of the CD4 mimic.
With reproduction of the properties of HIV-1 MNA Env, we generated an SHIV strain carrying Env through intracellular homologous recombination, as described previously (Fujita et al., 2013) with minor modifications (Fig. S2) . DNA fragments representing the 59 and 39 ends of the SHIV genome (fragments I and II, respectively) were amplified by PCR from the proviral DNA plasmid SHIV KS661. A DNA fragment containing env (fragment III) was amplified from cDNA of the HIV-1 MNA genome, which was prepared from virus particles (virion-associated RNA) in the culture supernatant of PM1/CCR5 cells (Yusa et al., 2005) infected with the virus. The PCR primers used are listed in Table S1 . Using a FuGENE HD transfection reagent, lipofection was performed on the C8166-CCR5 cells (Shimizu et al., 2006) to co-transfect them with 0.2 mg DNA. A cytopathic effect, presumably caused by the emerged recombinant virus, was observed on day 13 post-transfection. The emerged virus, designated SHIV MNA, carried the entire gp120 and three-quarters of gp41 from HIV-1 MNA Env (Fig. 1a) . The rest of Env was from SHIV KS661, the Env of which was derived from HIV-1 89.6 (Shinohara et al., 1999) . The CD4 binding site, and the regions and elements that reportedly interact with NBD-556 (Madani et al., 2008; Yoshimura et al., 2010) , are preserved in SHIV MNA Env (Fig. S3) . The virus was replication competent in PM1/CCR5 cells (data not shown).
As HIV-1 MNA has been suggested to be a CCR5-utilizing virus, we were intrigued as to whether SHIV MNA inherited the trait from the parental virus. We subjected SHIV MNA and the parental HIV-1 MNA to a co-receptor usage assay as described previously (Nishimura et al., 2010) , with minor modifications (Fig. S4 ). As expected, SHIV MNA was shown to utilize CCR5 as an entry coreceptor.
We next assessed the neutralization profiles of SHIV MNA in comparison with the parental HIV-1 MNA, as described previously (Li et al., 2005; Wei et al., 2002) . Both SHIV MNA and HIV-1 MNA showed essentially no neutralization by KD-247 up to 25 mg ml
21
, and 50 % neutralization was achieved at 50 mg ml 21 (Fig. 1b) . As the CD4 mimic, we employed YYA-021, a compound generated and characterized through studies concerning the structureactivity relationships of small molecules (Narumi et al., , 2011 (Narumi et al., , 2013 Yamada et al., 2010) . The compound was shown to be slightly less potent but to exhibit substantially lower toxicity than NBD-556, and was therefore a suitable choice for our purposes in future studies in animal models. SHIV MNA was resistant to neutralization by YYA-021 at all concentrations examined, except 25 and 50 mM, and showed a neutralization profile almost identical to that of HIV-1 MNA (Fig. 1c) . To further characterize the biological properties of SHIV MNA Env, a set of entry assays was conducted (Fig. S5) . The env genes cloned from SHIV MNA and HIV-1 MNA were utilized to generate pseudotyped viruses. These pseudotypes were inoculated into TZM-bl cells in the presence of increasing amounts of NBD-556, YYA-021 or sCD4. A control group was derived from another virus preparation pseudotyped with amphotropic murine leukemia virus (A-MLV) Env (Landau et al., 1991) . When the efficiency of entry was defined by intracellular luciferase activities, virtually no difference was observed between Envs of SHIV MNA and the parental HIV-1. Thus, SHIV MNA Env replicated in C8166-CCR5 cells retained sensitivity to small-molecule CD4 mimics and sCD4 comparable to that of HIV-1 MNA.
We then examined whether the synergistic neutralization of HIV-1 MNA by KD-247 antibody in the presence of NBD-556 would be reproduced when CD4 mimic was substituted by YYA-021. The synergistic neutralization effect of KD-247 and YYA-021 was reproduced in our experiments (Fig. 1d) . At 50 mg ml
, KD-247 barely achieved 50 % neutralization of HIV-1 MNA but resulted in 50 % neutralization at ,0.05 mg ml 21 in the presence of 20 mM of YYA-021.
Finally, to examine whether these two agents neutralized SHIV MNA in the same manner as the parental HIV-1, we conducted a neutralization assay with KD-247 in the presence of increasing amounts of YYA-021 (0, 5, 10, 20 and 40 mM) (Fig. 1e) . The neutralization curve of KD-247 against SHIV MNA showed an upward shift as the concentration of YYA-021 increased (Fig. 1e) , similar to the observations with HIV-1 (Fig. 1d) , indicating augmentation of neutralization, and complete neutralization of both viruses was achieved at 20 mM YYA-021 (Fig. 1d, e) . Based on these results, we concluded that the neutralization profile of SHIV MNA was comparable to that of HIV-1 MNA.
Reproduction of the neutralization characteristics of HIV-1 MNA in the newly generated SHIV prompted us to assess the ability of SHIV MNA to replicate in monkey cells. SHIV MNA, along with SIV239 and SHIV KS661, were normalized with infectious titres and inoculated into rhesus macaque PBMC preparations from four animals, as described previously (Fujita et al., 2013) (Fig. 2a) . SHIV KS661, a CXCR4-utilizing virus, replicated to the highest titres of all the viruses in all PBMC preparations. Compared with SHIV KS661, SIV239 replicated to lower titres. Under these experimental conditions, SHIV MNA showed productive replication in the cells with similar replication kinetics and peak titres to SIV239. Based on these results, we concluded that SHIV MNA was replication competent in primary monkey lymphocytes.
Productive replication of SHIV MNA in monkey PBMCs justified experimental infection of the virus in vivo. We inoculated 1.75610 5 TCID 50 SHIV MNA intravenously into a rhesus macaque and monitored plasma viral RNA burden and circulating CD4 + T-lymphocyte levels (Fig. 2b) . Plasma viral RNA burden reached a peak of 5.6610 6 copies ml 21 at 1 week post-infection (p.i.), and declined rapidly thereafter, reaching low levels of detection at 7 weeks p.i. (around 2.8610 2 copies ml
). Circulating CD4 + T-cell numbers showed a transient decrease around 1 week p.i., rebounded around 3 weeks p.i. and stabilized around 70 % of the pre-infection level from 4 weeks p.i. During the period of observation, the animal developed no obvious clinical manifestations related to lentivirus infection.
As SHIV MNA replicated in vivo without depleting helper T-cells, it was expected that the animal mounted an antiviral immune reaction. The production of antibody directed against Env was assessed by Western blotting, as described previously (Igarashi et al., 1999) . Purified Env protein (Advanced Biotechnologies) was used as the antigen (Fig. 3a) . Anti-Env antibody was detected at 3 weeks p.i., and the level of antibody judged by the intensity of the band increased gradually with time.
We next examined whether the animal generated neutralizing antibodies against SHIV MNA. Because plasma samples from this specimen exhibited high background activity, IgG was purified from these samples collected on day 0 and in week 24 p.i. using protein G spin columns (GE Healthcare Japan). While the IgG from day 0 exhibited no neutralizing activity (Fig. 3b) , as expected, the IgG collected at 24 weeks p.i. neutralized SHIV MNA, although a concentration .100 mg ml 21 was required to suppress replication of 100 TCID 50 of the input virus (Fig. 3c) .
We examined whether the observed marginal neutralization by the antibody could be enhanced by the presence of YYA-021. Upon addition of YYA-021 in the assay system, SHIV MNA became sensitive to IgG obtained at 24 weeks p.i. (Fig. 3c) , while no enhancement was identified from day 0 (Fig. 3b) .
In this study, we generated a replication-competent SHIV MNA strain carrying an Env resistant to the neutralizing mAb KD-247 but conditionally sensitive in the presence of the CD4 mimic YYA-021. As the observed neutralization characteristics were identical to those of HIV-1 MNA, which contributed the majority of the Env sequence to the chimaera, the utility of the CD4 mimic as a means of enhancing antibody-mediated virus neutralization should be assessed in the context of infection in vivo. This concept could be tested during the acute phase of SHIV MNA infection, during which the virus undergoes substantial replication. To examine the feasibility of CD4-mimicmediated enhancement of virus neutralization in the context of chronic infection, the conditions under which this type of intervention should be applied to HIV-1-infected patients in a clinical setting, the virus must be This study demonstrated that a CD4 mimic could modulate viral Env protein to be more susceptible to neutralization by less potent antibodies generated in the context of infection. During the early phase of infection, patients mount high titres of non-neutralizing antibodies directed against the V3 loop ( Davis et al., 2009a) . Patients with HIV-1 clade C generate anti-Env antibodies, including anti-CD4i antibodies, with poor neutralizing activity against recent infection (Gray et al., 2007) . It is possible that the CD4 mimic YYA-021 causes a conformational change in SHIV MNA Env, which renders sequestered epitope(s) accessible to potentially neutralizing IgG, such as ones directed against the V3 loop and CD4i.
The current study extended the previous study by Yoshimura et al. (2010) and used HIV-1 MNA belonging to clade B to generate a new SHIV strain carrying Env. The neutralization sensitivity of this strain is characteristically augmented in the presence of a small-molecule CD4 mimic. Similar observations by Decker et al. (2005) showed that infections of a wide range of HIV-1 strains of multiple clades or circulating recombinant forms elicit high titres of anti-CD4i antibodies. These anti-CD4i antibodies neutralize viruses as divergent as HIV-2 in the presence of sCD4 (Decker et al., 2005) . Taking these observations into account, small-molecule CD4 mimics such as YYA-021 could potentially enhance the neutralization activity of the antibodies directed against autologous viruses belonging not only to clade B but also to multiple HIV-1 strains of various clades and possibly even HIV-2. Our results pave the way for a novel therapeutic intervention based on administration of CD4 mimics to patients with HIV to facilitate control of the virus by their own antibodies.
